Cooley is advising Cardioxyl Pharmaceuticals on its sale to Bristol-Myers Squibb (BMS). Under the terms of the agreement, BMS will acquire all of the issued and outstanding capital stock of Cardioxyl for upfront and near-term milestone payments of up to $300 million and potential additional milestone payments of up to $1.78 billion. The transaction is expected to close before year end.
The acquisition strengthens BMS’s focus on heart failure and gives the company full rights to Cardioxyl’s CXL-1427, a novel drug that releases nitroxyl – a molecule that has demonstrated positive effects on heart muscle and vascular function. The drug is in development for acute decompensated heart failure.
Cardioxyl, based in Chapel Hill, North Carolina, is a privately-held, clinical stage biopharmaceutical company focused on the discovery and development of new classes of safe and effective therapies for the treatment of cardiovascular disease.
The Cooley M&A team advising Cardioxyl includes head of Cooley’s M&A group Barbara Borden, Christian Plaza, Ben Beerle, Matthew Silverman, Brandon Seal and Phillip McGill.
Related Posts:
- Cooley Advises CardioMEMS on Acquisition by St. Jude Medical
- Cooley – GeneWEAVE Sells to Roche for $425 MillionCooley advised GeneWEAVE Biosciences on its approximately $425 million sale to Roche. GeneWEAVE is a privately-held in vitro diagnostics company that is advancing clinical microbiology with diagnostic solutions. It helps healthcare providers in the fight against drug-resistant bacteria by enabling impactful surveillance programs, early therapy guidance and successful antibiotic stewardship. Roche Molecular Diagnostics is a subsidiary of F. Hoffman-La Roche, the world’s largest biotech company. The team advising GeneWEAVE included partners Mark Tanoury, Laura Medina and Barclay Kamb and associates Aaron Binstock, Kelsey Velemirovich and Carlton Fleming.
- Cooley Advises Underwriters on Onconova Therapeutics IPO
- Cooley Team Advises Excaliard Pharmaceuticals in Sale to Pfizer
- Isis Pharmaceuticals Completes Rule 144A Offering of $500 Million of Convertible Senior Notes
